Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.